
A D H O C A N N O U N C E M E N T

STRATEC continues to clearly increase sales and profit

Birkenfeld, July 29, 2003

The Board of Management of STRATEC Biomedical Systems AG, listed in the German Prime Standard, hereby issues a precautionary announcement of the results for the first half year of 2003, ending on June 30, 2003, pursuant to Section 15 of the German Securities Trading Law (WpHG).

STRATEC increased its net profit for the first half year (net profit as of January 1st to June 30, 2003) by 44.1% to EUR 0.526m. (2002: EUR 0.365m). This results in earnings per share (EPS) of EUR 0.16 (2002: EUR 0.11); (number of underlying shares: 3,298,400).

The overall performance and sales saw a clear two-digit growth. The first six months' sales rose by 25.9% to EUR 13.939m (2002: EUR 11.071m). In the same period the overall performance improved by 22.4% to EUR 14.876m (2002: EUR 12.155m).

At the end of the second quarter, STRATEC had 142 employees (June 30, 2002: 122).

Key Figures pursuant to IAS/IFRS at a glance:

Key Figures in EUR 000s	01/01/03-06/30/03	01/01/02-06/30/02	Change
Sales	13,939	11,071	+25.9%
Overall Performance	14,876	12,155	+22.4%
EBITDA	1,400	1,094	+28.0%
EBIT	964	701	+37.5%
EBT	863	590	+46.3%
Net income for the period	526	365	+44.1%

Issuer's information/explanatory remarks concerning this ad-hoc-announcement:

Due to the prevailing comparatively insignificant material relevance of STRATEC NewGen GmbH STRATEC Biomedical Systems AG will continue to present a non-consolidated financial statement. The operating loss of STRATEC NewGen GmbH is cumulatively processed in the 'Other Operating Expenses' and in the 'Other Accruals' of the parent company. STRATEC NewGen GmbH is a wholly-owned subsidiary of STRATEC Biomedical Systems AG.

About STRATEC Biomedical Systems AG:

STRATEC (<http://www.stratec-biomedical.de>) designs and manufactures fully automated systems for its partners in the fields of clinical diagnostics and biotechnology. These partners market such systems together with their own reagents to laboratories and research institutes around the world. The company develops its products on the basis of its own patented technologies. STRATEC is a publicly listed stock corporation. Shares in the company (ISIN: DE0007289001) are traded in the Prime Standard segment of the Frankfurt Stock Exchange and on other exchanges.

The detailed interim report will be mailed to our investors on August 14, 2003 and can be downloaded from our homepage from around 3 p.m., the same day.

Further information can be obtained from:

STRATEC Biomedical Systems AG
Investor Relations
André Loy
Gewerbestraße 37
75217 Birkenfeld
Tel: +49 (0) 70 82 / 79 16 43
Fax: +49 (0) 70 82 / 79 16 999
eMail: ir@stratec-biomedical.de